{"id":"lifitegrast-5-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Instillation site irritation"},{"rate":null,"effect":"Dysgeusia (taste perversion)"},{"rate":null,"effect":"Ocular discomfort"},{"rate":null,"effect":"Conjunctival hyperemia"}]},"_chembl":{"chemblId":"CHEMBL2048028","moleculeType":"Small molecule","molecularWeight":"615.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lifitegrast selectively inhibits LFA-1, an integrin expressed on lymphocytes, preventing their adhesion to intercellular adhesion molecule-1 (ICAM-1) on ocular surface cells. This blocks T-cell migration and infiltration into the eye, reducing the inflammatory cascade that characterizes dry eye disease. By decreasing lymphocyte-mediated inflammation at the ocular surface, the drug alleviates symptoms and improves tear production.","oneSentence":"Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist that blocks T-cell adhesion and infiltration into ocular tissues to reduce inflammation in dry eye disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:15.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"}]},"trialDetails":[{"nctId":"NCT04354545","phase":"","title":"Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2021-04-01","conditions":"Glaucoma, Ocular Surface Disease","enrollment":75},{"nctId":"NCT07025811","phase":"PHASE4","title":"A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-09","conditions":"Dry Eye Disease","enrollment":350},{"nctId":"NCT04030962","phase":"PHASE1, PHASE2","title":"A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-03-04","conditions":"Dry Eye Disease, Dry Eye Syndrome","enrollment":292},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT04297618","phase":"PHASE4","title":"The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers","status":"COMPLETED","sponsor":"University of Waterloo","startDate":"2021-07-07","conditions":"Dry Eye","enrollment":45},{"nctId":"NCT05102409","phase":"PHASE2","title":"An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-09-09","conditions":"Dry Eye","enrollment":56},{"nctId":"NCT05505292","phase":"PHASE4","title":"Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers","status":"COMPLETED","sponsor":"State University of New York College of Optometry","startDate":"2022-09-22","conditions":"Dry Eye","enrollment":32},{"nctId":"NCT04792580","phase":"EARLY_PHASE1","title":"The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease","status":"COMPLETED","sponsor":"Richard W Yee, MD","startDate":"2022-10-22","conditions":"Graft-versus-host-disease, Ocular Graft-versus-host Disease","enrollment":30},{"nctId":"NCT04120987","phase":"PHASE4","title":"Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra","status":"WITHDRAWN","sponsor":"Bucci Laser Vision Institute","startDate":"2021-05-31","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT04015219","phase":"NA","title":"Management of Signs and Symptoms Associated With Dry Eye Disease","status":"TERMINATED","sponsor":"BioTissue Holdings, Inc","startDate":"2018-07-18","conditions":"Dry Eye Syndromes","enrollment":3},{"nctId":"NCT04413253","phase":"PHASE4","title":"Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease","status":"TERMINATED","sponsor":"Eye Surgeons of Indiana","startDate":"2020-08-01","conditions":"Dry Eye Syndromes","enrollment":5},{"nctId":"NCT04669561","phase":"PHASE4","title":"The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2021-03-17","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT05045053","phase":"PHASE4","title":"Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking","status":"UNKNOWN","sponsor":"Benha University","startDate":"2021-02-01","conditions":"Corneal Disease","enrollment":40},{"nctId":"NCT02284516","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)","status":"COMPLETED","sponsor":"Shire","startDate":"2014-11-06","conditions":"Dry Eye Disease","enrollment":711},{"nctId":"NCT03952481","phase":"PHASE4","title":"Effect of Lifitegrast 5% on Tear Film Markers","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2021-03-01","conditions":"Dry Eye, Dry Eye Syndromes, Dry Eyes Chronic","enrollment":""},{"nctId":"NCT03866629","phase":"","title":"The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"MDbackline, LLC","startDate":"2018-12-20","conditions":"Dry Eye","enrollment":103},{"nctId":"NCT03686878","phase":"PHASE4","title":"Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness","status":"COMPLETED","sponsor":"EV Clinical Trials","startDate":"2016-12-16","conditions":"Contact Lens, Contact Lens Discomfort, Contact Lens Dryness","enrollment":21},{"nctId":"NCT03451396","phase":"PHASE4","title":"Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms","status":"COMPLETED","sponsor":"Lifelong Vision Foundation","startDate":"2016-12-12","conditions":"Dry Eye","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xiidra","Xiidra 5% Ophthalmic Solution"],"phase":"marketed","status":"active","brandName":"Lifitegrast 5% Ophthalmic Solution","genericName":"Lifitegrast 5% Ophthalmic Solution","companyName":"Research Insight LLC","companyId":"research-insight-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist that blocks T-cell adhesion and infiltration into ocular tissues to reduce inflammation in dry eye disease. Used for Dry eye disease (keratoconjunctivitis sicca).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}